Free Alerts   Login
Health Care › Orthopedic, Prosthetic And Surgical Appliances And Supplies

ZBH Stock Price Correlated With Zimmer Biomet Holdings Financials

ZBH Stock Price vs. Quarterly
ZBH
Income Statement
Cash Flow
Balance Sheet

ZBH Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

ZBH Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

ZBH Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group
23,859,325 sh
-75,107 sh
0%
$2,903,681
$217,759
Blackrock.
18,704,829 sh
-2,926,347 sh
-14%
$2,276,376
-$151,073
Dodgex
11,474,535 sh
6,647,810 sh
138%
$1,396,451
$854,796
Price T Rowe Associates /Md/
9,426,866 sh
1,458,359 sh
18%
$1,148
$254
State Street
9,311,453 sh
296,192 sh
3%
$1,135,415
$121,579
Invesco.
6,205,518 sh
-221,253 sh
-3%
$755,212
$33,998
American Century Companies
5,932,322 sh
5,932,322 sh
NEW
$721,964
$721,964
Primecap Management Co/Ca/
5,086,578 sh
484,151 sh
11%
$619,037
$102,553
Geode Capital Management
4,602,984 sh
98,675 sh
2%
$558,698
$54,323
JPMorgan Chase
3,827,830 sh
382,703 sh
11%
$465,849
$79,236
Victory Capital Management
3,199,302 sh
118,839 sh
4%
$389,355
$43,665
Van Eck Associates
2,838,558 sh
543,344 sh
24%
$345
$87
Morgan Stanley
2,780,085 sh
301,394 sh
12%
$338,337
$60,177
Allspring Global Investments Holdings
2,760,021 sh
386,019 sh
16%
$335,895
$69,485
Boston Partners
2,623,748 sh
-71,084 sh
-3%
$319,316
$16,951
Northernrp
2,501,922 sh
-151,412 sh
-6%
$304,484
$6,727
Norges Bank
2,193,062 sh
2,193,062 sh
NEW
$266,896
$266,896
Neuberger Berman Group
2,178,478 sh
-265,524 sh
-11%
$265,118
-$9,163
Legal & General Group Plc
2,137,749 sh
238,418 sh
13%
$260,164
$47,020
Camber Capital Management Lp
1,925,000 sh
75,000 sh
4%
$234,273
$26,666
COMPANY PROFILE
1.

Business

We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.  We collaborate with healthcare professionals around the globe to advance the pace of innovation.  Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues.  Together with healthcare professionals, we help millions of people live better lives.
The words “Zimmer Biomet,” “we,” “us,” “our,” “the Company” and similar words refer to Zimmer Biomet Holdings, Inc. and its subsidiaries.  “Zimmer Biomet Holdings” refers to the parent company only.  In 2015, we completed our merger with LVB Acquisition, Inc., the parent company of Biomet, Inc. (“Biomet”).
Risks and Uncertainties - Our results have been and are expected to continue to be impacted by the COVID-19 global pandemic. The vast majority of our net sales are derived from products used in elective surgical procedures which continue to be deferred due to precautions in certain markets and staffing shortages.  The consequences of COVID-19 continue to be extremely fluid and there are many market dynamics that are difficult to predict.  The COVID-19 pandemic may have an unfavorable effect on our financial position, results of operations and cash flows in the near term.
Planned Spinoff - On February 5, 2021, we announced our intention to pursue a plan to spin off our Spine and Dental businesses into a new public company named ZimVie Inc. (“ZimVie”).  The planned transaction is intended to benefit our stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers and, therefore, achieve faster growth and deliver greater value for all stakeholders.  The transaction is intended to qualify as a tax-free distribution, for U.S. federal income tax purposes, to U.S. stockholders of new publicly traded stock in ZimVie.  The expected completion date of the spinoff is March 1, 2022.  Our Board of Directors has declared a pro rata dividend of 80.3% of the outstanding common stock of ZimVie to our stockholders of record as of the close of business on February 15, 2022.  As a result of the dividend, our stockholders will receive one share of ZimVie common stock for every ten shares of our common stock.  Immediately following the dividend, we will retain 19.7% of the outstanding shares of ZimVie common stock, which we intend to divest after the separation in a tax-efficient manner.

Free historical financial statements for Zimmer Biomet Holdings Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 56 quarters since 2010. Compare with ZBH stock chart to see long term trends.

Data imported from Zimmer Biomet Holdings Inc SEC filings. Check original filings before making any investment decision.